NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
NewCo is a new transaction model developed by Chinese innovative drug companies in response to...
Sciwind Biosciences
Sino Biopharmaceutical and Sciwind Biosciences Partner on CPX102 Development
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced a strategic partnership with compatriot firm Sciwind Biosciences...
SciWind Bio and Verdiva Bio Partner on Global Development of Obesity Therapies
On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement...
Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management
Sciwind Biosciences Co., Ltd has received a significant boost as the National Medical Products Administration...
Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes
China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has...
China’s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea
China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South...
Sciwind Biosciences’ Ecnolgutide Shows Promising Phase III Results in Type 2 Diabetes Treatment
Sciwind Biosciences Co., Ltd, a China-based pharmaceutical company, has released the latest topline Phase III...
Sciwind Biosciences Leads China’s Anti-Obesity Drug Market with GLP-1 Analog Ecnoglutide
Sino-US biotech Sciwind Biosciences Co., Ltd has positioned itself as a frontrunner in China’s race...
Sciwind Biosciences Initiates Phase III Trial for Ecnoglutide in Type 2 Diabetes
Hangzhou-based Sciwind Biosciences Co., Ltd has announced the first subject dosing in a Phase III...
Sciwind Biosciences Initiates US Phase I Study for GLP-1 Agonist XW014
China-based Sciwind Biosciences Co., Ltd has announced the initiation and first patient dosing of a...
Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development
Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration...
Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study
Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...
Sciwind Biosciences’ XW003 Hits Phase II Trial Goals in Type 2 Diabetes Treatment
Hangzhou-based biopharma Sciwind Biosciences Co., Ltd announced positive results from a 20-week Phase II trial...